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Discussion
Alpha-1 antitrypsin deficiency (AATD) is an autosomal co-
dominant condition resulting in decreased or absent levels of 
alpha-1 antitrypsin (AAT) which is a protease produced in the 
liver. This allows the uninhibited proteolytic action of 
neutrophil elastase to overtake the lungs resulting in 
degradation of lung tissue and early onset (prior to the fourth or 
fifth decade) emphysema and chronic obstructive pulmonary 
disease (COPD) (Hatipoglu, Umur & Stoller, 2016). Exposure to 
environmental pollutants and cigarette smoke greatly increase 
neutrophil elastase activity and therefore exacerbate lung 
destruction in AATD individuals.  It is thought that similar 
inflammatory reactions occur in the skin resulting in vasculitis 
and panniculitis. In addition, intrahepatic accumulation of the 
defective protein may cause cirrhosis or primary liver 
carcinoma. This condition accounts for 2%-5% of chronic 
obstructive pulmonary disease cases in America (Diaz,J.A, 
Minami, 2017) and is thought to be most common in 
individuals of Northern European decent (Hatipoglu, Umur & 
Stoller, 2016).
Statement of the Problem
References
Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that 
results in debilitating illnesses like: emphysema, COPD, liver 
disease, and panniculitis. AATD is highly under-diagnosed 
based on epidemiologic and population studies that suggest 
that fewer than 10% of the 60,000-100,000 individuals in 
the U.S. suspected to have severely deficient alleles have 
been identified ( Rahaghi et al., 2012). This study examines 
strategies aimed at improving detection of AATD. The findings  
indicate that utilizing flags to alert providers of the need for 
AATD testing initiated by RTs or automated within EMR systems 
are effective strategies for increasing testing rates and potentially 
improving detection of emphysema and COPD secondary to 
AATD therefore eliminating diagnostic delays and improving 
prognosis for those affected.
• What are the barriers to detection of AATD? 
• Are there effective strategies that may be implemented 
to overcome barriers to recognition and decrease 
diagnostic delays allowing for interventions that may 
decrease progressive loss of lung function in COPD 
patients with AATD?
Research Questions
A search of peer reviewed journal articles was performed 
utilizing electronic databases including: PubMed, Cochrane, 
and Clinical Key. Several articles published between 2002 
and 2017 were retrieved and reviewed including those 
regarding the pathophysiology and prevalence of alpha-1 
deficiency, guidelines for testing and management of 
patients with AATD, current and emergent therapies for 
AATD, barriers to diagnosis, and strategies for improved 
diagnosis. One systematic review of articles published 
between January 2002 and December 2014 regarding 
practice guidelines for diagnosis and management of AATD 
patients was reviewed. An observational study published in 
2010 that analyzed barriers to detection by assessing the 
level of knowledge of AATD among internal medicine house 
officers and respiratory therapists was included. Three 
observational studies published between 2009 and 2014 
aimed at analyzing processes for improving detection of 
alpha-1 antitrypsin deficiency were included. Information 
was also obtained from the Alpha-1 Foundation website and 
personal interviews with Ronald Reilkoff, M.D. (University of 
Minnesota Pulmonary, Allergy, Critical Care & Sleep 
Medicine) and Mary Davis (Sales Director, Grifols USA). 
Despite guidelines from the American Thoracic Society and 
the European Respiratory Society regarding testing for AATD, 
the disorder remains highly under-diagnosed. Furthermore, 
individuals report long delay times (averaging 5-7years) and 
visits to multiple providers between onset of symptoms and 
diagnosis which delays opportunities for lifestyle modifications 
and potential treatment with augmentation therapy that may 
improve prognosis(Hatipoglu, Umur & Stoller, 2016).
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Primary care is often the first point of entry for many patients 
with obstructive airway diseases making it an ideal 
environment in which to implement new strategies for 
improved detection of alpha-1 antitrypsin deficiency. Fromer 
(2010) proposed the following process maps aimed at 
improving diagnosis and management of AATD in the primary 
care setting.
Utilizing Respiratory Therapists and Automated EMR 
algorithms to flag patients for testing:
Rahaghi et al. (2009) analyzed the effects of a physician 
alert for AATD testing generated by respiratory therapists 
following abnormal PFT results. During the pre-alert 
period, 6% of included patients underwent testing for 
AATD compared to 13% in the physician alert phase 
(p=0.04). In 2011,Jain, McCarthy, Xu, and Stoller conducted 
a similar study at the Cleveland Clinic in Ohio utilizing an 
EMR based flag for testing. The study included 979 subjects 
during a pre-alert period. 4.7% were referred for testing 
resulting in 8.9% found to have AATD based on serum 
levels. Phenotyping of those with low serum levels, resulted 
in 3.2% with genotype PI ZZ. During the alert period, 624 
patients were determined eligible and the rate of testing 
increased substantially to 15.1%, P < 0.001. In conclusion, 
the studies strongly suggested that utilizing respiratory 
therapists and EMR flags to identify individuals for testing 
based on PFT results substantially increased rates for 
testing individuals clinically indicated at risk for AATD 
(Rahaghi et al., 2009). 
Potential Barriers to Detection of AATD:
• Lack of knowledge regarding Alpha-1 among providers 
and patients.
• Perception among providers that treatment is ineffective.
• Patient fear that diagnosis will affect their ability to obtain 
life or health insurance or fear of emotional impact.
• Cost associated with testing.
Addressing the Barriers and Exploring Strategies to 
Overcome Them:
Overcoming the Cost of Testing and Providing Patient 
and Provider resources regarding diagnosis and 
Management of AATD:
The Alpha-1 Foundation and many of the pharmaceutical 
manufacturers of augmentation offer free testing kits for 
evaluation of AAT serum level and genotype using dried blood 
spot PCR eliminating this barrier. In addition, the Alpha-1 
Foundation offers genetic counseling services for those 
identified with AATD. In addition, the foundation provides and 
array of educational offerings regarding AATD diagnosis and 
treatment to clinicians.(Alpha-1 Foundation, n.d.)
Knowledge of AATD
Taliercio, Chatburn, and Stoller, 2010, conducted a study 
assessing the knowledge of AATD among internal 
medicine house officers and respiratory therapists (RTs) at 
the Cleveland Clinic. There was no statistically significant 
difference between the physician and RTs mean scores of 
54% and 52%, P= .25. Half of physician scores were 
below 55% with that being the median for the group. 
The median for RTs was 50%. Those who rated 
themselves as “somewhat knowledgeable” on self-
assessment scored highest with physician scores of 
60% correct and RT scores of 56%, P= < .001. Physician 
scores did not change based on post-graduate education 
level (P= .94), but RTs with 4-year degrees had a higher 
mean score than those graduating from 2 year programs 
(56% vs 50%) (Taliercio, Chatburn, & Stoller, 2010). 
Effectiveness of Augmentation with Human Plasma 
Derived Alpha-1 Protein
The American Thoracic Society currently recommends 
augmentation therapy with Alpha-1 antitrypsin derived from 
human plasma for mild to moderate COPD (FEV1 of 35%-
65%) and alpha-1 antitrypsin deficiency. Despite early 
randomized control trials that failed to prove improvement in 
lung function of AATD individuals receiving augmentation 
therapy while using spirometry and FEV1 as measures, 
more recent studies have noted reductions in the loss of 
lung density when subjects were assessed with Computed 
Tomography rather than spirometry. In addition, 
observational benefits such as: decreased mortality, 
reduction of inflammatory markers in sputum, and reduced 
rates of respiratory tract infections have been noted in those 
who received augmentation compared to those who did not. 
The FDA has approved augmentation therapy for mild to 
moderate COPD due to AATD on the basis of biochemical 
efficacy, which is described as the ability to raise serum 
levels to the established protective threshold of 11µM or 
57mg/dL (Hatipoglu, Umur & Stoller, 2016). 
The Genetic Information Nondiscrimination Act (GINA) 
of 2008 protects those diagnosed with genetic 
disorders from discrimination when applying for 
health insurance and employment (NIH, 2013)
Figure 3a. Proposed process map for AATD screening in the primary care setting
Figure 3b. Proposed diagnosis algorithm for AATD planned care follow-up in the primary 
care setting.
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